We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pulsating ElectroMagnetive Treatment (PEMF) at Treatment Resistant Depression (PEMFII)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01353092
First Posted: May 12, 2011
Last Update Posted: August 26, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Per Bech, Hillerod Hospital, Denmark
  Purpose
In this study patients with treatment resistant depression, as defined by Harold Sackeim, is subjected to daily sessions, for eight weeks, with Pulsating ElectroMagnetive Treatment (PEMF). Treatment is given two times a day, in the morning and in the afternoon. Patients are randomized into two groups. In group A patients receive active treatment both morning and afternoon. In group B patients receive one sham and one active treatment. The study is double-blind as neither the assessors or patients are aware of treatment allocation. Each session lasts 30 minutes. Patients are psychometrically assessed weekly for depression severity and side effect. After this intervention period patients are followed for further three weeks without PEMF treatment. Patients are on unchanged medication for the whole of the study period.

Condition Intervention Phase
Treatment Resistant Depression Device: Re5 Pulsating ElectroMagnetic Fields Device: Re5 Pulsating ElectroMagnetic Fields (PEMF) Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: PEMF Treatment in Patients With Treatment Resistant Depression in On-going Antidepressant Drug Therapy. A Randomized, Double-blind, Clinically Controlled, Dose-response PEMF Trial for a Duration of Eight Weeks

Resource links provided by NLM:


Further study details as provided by Per Bech, Hillerod Hospital, Denmark:

Primary Outcome Measures:
  • Hamilton depression rating scale [ Time Frame: Every week for 11 weeks ]
    Interviewer based rating scale to measure severity of depression


Secondary Outcome Measures:
  • UKU [ Time Frame: Every week for 11 weeks ]
    Side effect scale


Enrollment: 65
Study Start Date: April 2011
Study Completion Date: June 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Active PEMF twice daily

Re5 treatment helmet using Pulsating ElectroMagnetic Field:

Intervention: 30 minutes of active PEMF therapy in the morning and 30 minutes of active PEMF therapy in the afternoon

Device: Re5 Pulsating ElectroMagnetic Fields

Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF):

30 minutes of active PEMF therapy in the morning and 30 minutes of active PEMF therapy in the afternoon

Other Name: T-PEMF = Transcranially applied PEMF
Active Comparator: Active PEMF once daily

Re5 treatment helmet using Pulsating ElectroMagnetic Field:

Intervention: 30 minutes of sham therapy and 30 minutes of active therapy (morning or afternoon)

Device: Re5 Pulsating ElectroMagnetic Fields (PEMF)

Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF):

30 minutes of sham therapy and 30 minutes of active therapy (morning or afternoon)

Other Name: T-PEMF = Transcranially applied PEMF

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Treatment resistant Major depression (grade 3 Sackeim criteria)
  • Age above 18 and below 85
  • Hamilton (17 item version) score above 12
  • Unchanged psychopharmacological treatment for last five weeks.

Exclusion Criteria:

  • suicidality above 2 on item three on Hamilton scale or,earlier PEMF treatment
  • dementia or similar cognitive impairment
  • psychotic disorder
  • abuse of alcohol or drugs
  • pregnant or lactating women
  • insufficient birth control measures
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01353092


Locations
Denmark
Psychiatric Research Unit, Mental Health Centre North Zealand
Hilleroed, Denmark, 3400
Sponsors and Collaborators
Hillerod Hospital, Denmark
Investigators
Principal Investigator: Marianne Lunde, Coordinator Mental Health Centre North Zealand Psychiatric Research Unit
  More Information

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Per Bech, Professor, Hillerod Hospital, Denmark
ClinicalTrials.gov Identifier: NCT01353092     History of Changes
Other Study ID Numbers: 26.04.2010
First Submitted: April 27, 2011
First Posted: May 12, 2011
Last Update Posted: August 26, 2015
Last Verified: August 2015

Keywords provided by Per Bech, Hillerod Hospital, Denmark:
Randomized Controlled Trial
Major depression
Hamilton
PEMF

Additional relevant MeSH terms:
Depression
Depressive Disorder
Depressive Disorder, Treatment-Resistant
Behavioral Symptoms
Mood Disorders
Mental Disorders